Chris is a Partner of Bridgepoint with responsibility for Bridgepoint Europe. He also sits on the Firm’s Executive Committee and is a member of its Investment Advisory Committee. He joined the Firm in 1997.
He currently sits on the board of Vermaat and historical transactions include Element, PharmaZell, ACT, Vitamin Well, LGC, ERM, Pret A Manger, CEG, and the delisting of Exova.
Chris has a BSc from Exeter University and is ACA qualified from his time spent working at PwC prior to joining Bridgepoint.
To access investor reports through the web based reporting facility, please fill in the form to register for an account.
The information submitted on this form will be used for the sole purpose of registering you as an account user and will not be shared with third parties.